

Supplementary material

Table 1. Etiology

Pathogen	Study population (n = 164)	COVID-19 (n = 40)	Influenza (n = 25)	Bacterial (n = 99)
Virus, n (%)				
SARS-CoV-2	40 (24.4)	40 (100.0)	0 (0.0)	0 (0.0)
Influenza A	25 (15.2)	0 (0.0)	25 (100.0)	0 (0.0)
Parainfluenza	1 (0.6)	0 (0.0)	0 (0.0)	1 (1.0)
Bacteria, n (%)				
<i>Haemophilus influenzae</i>	31 (18.9)	1 (2.5)	0 (0.0)	30 (30.3)
<i>Streptococcus pneumoniae</i>	18 (11.0)	0 (0.0)	0 (0.0)	18 (18.2)
<i>Escherichia coli</i>	10 (6.1)	1 (2.5)	0 (0.0)	9 (9.1)
<i>Staphylococcus aureus</i>	7 (4.3)	0 (0.0)	0 (0.0)	7 (7.1)
<i>Mycoplasma pneumoniae</i>	7 (4.3)	0 (0.0)	0 (0.0)	7 (7.1)
<i>Legionella pneumophila</i>	5 (3.0)	0 (0.0)	0 (0.0)	5 (5.1)
<i>Moraxella catarrhalis</i>	5 (3.0)	1 (2.5)	0 (0.0)	4 (4.0)
<i>Pseudomonas aeruginosa</i>	4 (2.4)	0 (0.0)	0 (0.0)	4 (4.0)
Others	49 (29.9)	4 (10.0)	0 (0.0)	45 (45.5)

Table 2. Comorbidities

Comorbidities, n (%)	COVID-19 (n = 40)	Influenza (n = 25)	Bacterial (n = 99)
Hypertension	18 (45)	15 (60)	42 (42)
Asthma	5 (13)	5 (20)	18 (18)
Diabetes	5 (13)	6 (24)	14 (14)
Malignancy	4 (10)	2 (8)	15 (15)
Cerebrovascular disease	4 (10)	5 (20)	14 (14)
COPD	3 (8)	10 (40)	35 (35)
Heart failure	1 (3)	3 (12)	12 (12)
Other neurological disease	2 (5)	2 (8)	4 (4)
Chronic liver disease	0 (0)	1 (4)	3 (3)
Chronic kidney disease	0 (0)	1 (4)	2 (2)

Table 3. Laboratory results

	COVID-19 (n = 40)	Influenza (n = 25)	Bacterial (n = 99)
Leucocytes, median (IQR), $\times 10^9$ cells/L	6.2 (4.8-8.3)	8.6 (5.9-11.2)*	10.8 (8.6-13.7)***
Lymphocytes, median (IQR), $\times 10^9$ cells/L	0.90 (0.80-1.40)	1.35 (0.90-1.83)	1.20 (0.80-1.80)
Monocytes, median (IQR), $\times 10^9$ cells/L	0.4 (0.3-0.7)	0.7 (0.4-0.9)	0.8 (0.5-1.0)***
Neutrophils, median (IQR), $\times 10^9$ cells/L	4.6 (3.1-5.9)	6.2 (3.9-9.3)	8.5 (6.2-10.3)***
Thrombocytes, median (IQR), $\times 10^9$ cells/L	235 (171-305)	189 (180-299)	261 (192-341)
Hemoglobin, mean (SD), mmol/L	8.0 (0.9)	7.7 (1.0)	7.4 (1.0)**
Ferritin, median (IQR), $\mu\text{g/L}$	775 (440-1460)	305 (245-380)***	322 (191-553)***
Albumin, mean (SD), g/L	26 (4)	28 (1)	26 (5)
Creatinine, median (IQR), $\mu\text{mol/L}$	76 (62-87)	70 (57-87)	74 (58-86)
Urea, median (IQR), mmol/L	5.6 (3.7-7.8)	6.3 (5.1-8.0)	7.1 (4.9-10.6)
D-dimer, median (IQR), FEU/L	1.4 (1.1-1.6)	2.2 (1.0-3.3)	1.7 (0.7-2.6)
INR, median (IQR)	1.0 (1.0-1.1)	1.1 (1.0-1.1)	1.1 (1.0-1.1)
ALAT, median (IQR), U/L	26 (18-37)	23 (19-39)	23 (13-39)
Bilirubin, median (IQR), $\mu\text{mol/L}$	10 (9-12)	7 (5-10)**	8 (6-13)

LDH, median (IQR), U/L	276 (230-344)	245 (198-297)	189 (164-219)***
Procalcitonin, median (IQR), µg/L	0.09 (0.07-0.25)	0.11 (0.08-0.24)	0.31 (0.10-3.84)**

Note: ALAT: Alanine aminotransferase, INR: International normalized ratio, LDH: Lactate dehydrogenase. * $P < 0.05$; ** $P < 0.01$, *** $P < 0.001$: different from COVID-19. Comparisons were done by Kruskal Wallis Test with Dunn's post hoc test or one-way ANOVA with Tukey post hoc test.